Home › Research › Brain tissue and pathology
The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study
Aleksandra Ochneva, Valeriya Zakurazhnaya, Yana Zorkina, Olga V. Abramova, Valeriya M. Ushakova, Anna M. Tsurina, Elizaveta Golubeva, Olga Ivanovna Gurina et al.. Journal of Alzheimer s Disease, 2025-06-16
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Alzheimer's disease (AD), a neurodegenerative condition and major subtype of dementia, is often preceded by mild cognitive impairment (MCI), a transitional stage before dementia. While cerebrospinal fluid (CSF) biomarkers are widely used for diagnosing AD and MCI, blood-based biomarkers offer the advantage of easier accessibility. This study aimed to compare blood levels of nine biomarkers among healthy controls, patients with MCI, and those with dementia, and to evaluate their potential for predicting AD progression. Objective The aim of our study was to study biomarkers in three groups of elderly people with varying degrees of cognitive decline. Methods The study included 234 participants aged 65 and older with dementia, MCI, or no cognitive impairment. Cognitive function was assessed using the Mini-Mental State Examination scale. Plasma levels of nine biomarkers, including amyloid-β 40 (Aβ 40 ), amyloid-β 42 (Aβ 42 ), KLK-6, NCAM-1, FGF-21, neurogranin, Tau, pTau181, and TDP-43, were measured by multiplex analysis. Results Aβ 42 levels were higher in the MCI group compared to controls (p = 0.002) and in dementia patients compared to those with MCI (p = 0.018). TDP-43 and neurogranin levels were elevated in dementia patients compared to both the MCI group (p < 0.05 and p < 0.01, respectively) and controls (p < 0.05 and p < 0.001, respectively). Neurogranin levels were also higher in the MCI group compared to controls (p < 0.001) and significantly differed between MCI and dementia (p = 0.003). Conclusions Aβ 42 , TDP-43, and neurogranin show potential as blood-based biomarkers for cognitive decline and may provide insight into the pathogenesis of neurodegeneration.
What this study adds
Evidence grade: Low
The record lists 234 participants. In this cross-sectional study of 234 participants, blood levels of TDP-43 and neurogranin were elevated in dementia patients compared to those with MCI and controls. This suggests these blood markers may help distinguish dementia stages, but the study cannot show whether they predict progression over time.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ochneva, A., Zakurazhnaya, V., Zorkina, Y., Abramova, O. V., Ushakova, V. M., Tsurina, A. M., et al. (2025). The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251350385
Vancouver
Ochneva A, Zakurazhnaya V, Zorkina Y, Abramova OV, Ushakova VM, Tsurina AM, et al. The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251350385. PMID: 40518820.
BibTeX
@article{ochneva2025-40518820,
author = {Ochneva, Aleksandra and Zakurazhnaya, Valeriya and Zorkina, Yana and Abramova, Olga V. and Ushakova, Valeriya M. and Tsurina, Anna M. and Golubeva, Elizaveta and Gurina, Olga Ivanovna and others},
title = {{The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study}},
journal = {Journal of Alzheimer s Disease},
year = {2025},
doi = {10.1177/13872877251350385},
pmid = {40518820},
url = {https://doi.org/10.1177/13872877251350385}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Aβ 42 levels were higher in the MCI group compared to controls (p = 0.002) and in dementia patients compared to those with MCI (p = 0.018).
- TDP-43 and neurogranin levels were elevated in dementia patients compared to both the MCI group (p < 0.05 and p < 0.01, respectively) and controls (p < 0.05 and p < 0.001, respectively).
- Neurogranin levels were also higher in the MCI group compared to controls (p < 0.001) and significantly differed between MCI and dementia (p = 0.003).
Why it matters
In this cross-sectional study of 234 participants, blood levels of TDP-43 and neurogranin were elevated in dementia patients compared to those with MCI and controls. This suggests these blood markers may help distinguish dementia stages, but the study cannot show whether they predict progression over time.
Study details
- Participants234
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 37 of the 96 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 234 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Lomonosov Moscow State University: institution h-index 708 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40518820) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 37 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 96 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Related studies in Brain tissue and pathology from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.